Compare · CBLL vs SLNO
CBLL vs SLNO
Side-by-side comparison of CeriBell Inc. (CBLL) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBLL and SLNO operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO is the larger of the two at $2.76B, about 3.9x CBLL ($705.4M).
- Over the past year, CBLL is up 8.0% and SLNO is down 32.2% - CBLL leads by 40.2 points.
- CBLL has been more active in the news (15 items in the past 4 weeks vs 2 for SLNO).
- SLNO has more recent analyst coverage (12 ratings vs 8 for CBLL).
- Company
- CeriBell Inc.
- Soleno Therapeutics Inc.
- Price
- $18.56+0.30%
- $53.02+0.08%
- Market cap
- $705.4M
- $2.76B
- 1M return
- +12.76%
- +0.76%
- 1Y return
- +7.97%
- -32.20%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 2014
- News (4w)
- 15
- 2
- Recent ratings
- 8
- 12
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest CBLL
- Director Taylor Joseph Michael sold $101,255 worth of shares (5,500 units at $18.41), decreasing direct ownership by 8% to 61,573 units (SEC Form 4)
- President and CEO Chao Xingjuan sold $714,870 worth of shares (39,000 units at $18.33) as part of a pre-agreed trading plan and exercised 25,000 shares at a strike of $4.70, decreasing direct ownership by 2% to 816,317 units (SEC Form 4)
- Ceribell Announces New Critical Care Medicine Publication Reinforcing Link Between Seizure Burden Measured by Clarity AI Algorithm and Neurological Outcomes
- Director Tammenoms Bakker Juliet was granted 7,838 shares, increasing direct ownership by 51% to 23,284 units (SEC Form 4)
- Director Parvizi Josef was granted 7,838 shares, increasing direct ownership by 51% to 23,284 units (SEC Form 4)
- Director Rogers Erica J. was granted 7,838 shares, increasing direct ownership by 31% to 33,054 units (SEC Form 4)
- Director Burke William W was granted 7,838 shares, increasing direct ownership by 45% to 25,229 units (SEC Form 4)
- Director Taylor Joseph Michael was granted 7,838 shares, increasing direct ownership by 13% to 67,073 units (SEC Form 4)
- Director Robertson Rebecca B was granted 7,838 shares, increasing direct ownership by 42% to 26,587 units (SEC Form 4)
- CeriBell Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest SLNO
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Business Officer Norrett Kevin returned 17,786 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Commercial Officer Manning Meredith returned 64,507 shares to the company, closing all direct ownership in the company (SEC Form 4)